ClinicalTrials.gg
CompletedNCT03073200Ixora-pedsUpdated Sep 27, 2021Results posted

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

A Phase 3 interventional study of Ixekizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 69 sites in 13 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-09-27.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
10th of 22
201 · median 156
Started
2017
with 1 other
Phase 3
11 of 22
none open now
Registered
13th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 13th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • children
  • psoriasis treatment
  • adolescents
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of moderate-to-severe plaque-type psoriasis for at least 6 months prior to baseline as determined by the investigator.
  • Have Psoriasis Area and Severity Index (PASI) score ≥12 and a Static Physician Global Assessment (sPGA) ≥3 and body surface area involvement ≥10% at screening and baseline.
  • Are candidates for phototherapy or systemic treatment or considered by the investigator as not adequately controlled by topical therapies.
  • Male subjects agree to use a reliable method of during the study.
  • Female subjects: Participants of childbearing age or who are sexually active who test negative for pregnancy must be counselled and agree to use either 1 highly effective method of contraception or 2 acceptable methods of contraception combined for the duration of the study and for at least 12 weeks following the last dose of study drug, or remain abstinent during the study and for at least 12 weeks following the last dose of study drug.
  • Both the child or adolescent and a parent or legal guardian are able to understand and fully participate in the activities of the clinical study and sign their assent and consent, respectively.
  • All immunizations are up-to-date in agreement with current immunization guidelines as noted by country specific paediatric authorities (e.g., the American Academy of Paediatrics). Note, subjects who are not up to date or have never been immunized are not to be enrolled in the trial.

Exclusion criteria

Exclusion Criteria:

  • Have pustular, erythrodermic, and/or guttate forms of psoriasis.
  • Have drug-induced psoriasis.
  • Have clinical and/or laboratory evidence of untreated latent or active tuberculosis (TB).
  • Participants with a documented history of immune deficiency syndrome.
  • Have any other active or recent infection, including chronic or localized infections, within 4 weeks of baseline.
  • Subjects with a known history of , lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly unless ruled out by .
  • Have used any therapeutic agent targeted at reducing interleukin-17.
  • Have received other therapies within the specified time frames prior to screening (see below):

    • adalimumab and infliximab 60 days, abatacept 90 days, anakinra 7 days, or any other biologic disease-modifying antirheumatic drug 5 half-lives.
    • systemic therapy for psoriasis and psoriatic arthritis (PsA) (other than above, eg, methotrexate, cyclosporine), phototherapy (eg, photochemotherapy [psoralen plus ultraviolet A]) in the previous 4 weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.

    Drug: Ixekizumab

  • Placebo comparator
    Placebo

    Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.

    Drug: Placebo

  • Experimental
    Open-Label Etanercept

    Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.

    Drug: Etanercept

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

  • Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)

    PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total body surface area (BSA) affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

    Time frame: Week 12

  2. Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab)

    Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)

    PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%.Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

    Time frame: Week 12

  2. Percentage of Participants With a sPGA (0)

    Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis. An sPGA assessed as 0 represents a clinically important endpoint indicating complete resolution of plaque psoriasis.

    Time frame: Week 12

  3. Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

    PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

    Time frame: Week 12

  4. Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)

    PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

    Time frame: Week 4

  5. Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1)

    Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.

    Time frame: Week 4

  6. Percentage of Participants With an Improvement of ≥4 in Those Who Had a Baseline Itch Numeric Rating Scale (NRS) Score of ≥4

    Itch Numeric Rating Scale (NRS): is a single-item, patient-reported outcome (PRO) measure designed to capture the overall severity of a participant's itching due to his/her psoriasis by having the patient circle the integer that describes the worst level of itching in the past 24 hours on an 11-point NRS anchored at 0 representing "no itching" and 10 representing "worst itch imaginable.

    Time frame: Week 12

  7. Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) (0/1)

    DLQI is a validated, dermatology-specific, patient reported measure that evaluates participant's health-related quality of life. It consists of 10 items that are grouped in 6 domains: symptoms \& feelings, daily activities, leisure, work \& school , personal relationships, \& treatment. The recall period of this scale is over the "last week." Response categories and corresponding scores are: Very much = 3, A lot = 2, A little = 1, Not at all = 0, Not relevant = 0. A DLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment). CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. A CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment).

    Time frame: Week 12

  8. Change From Baseline on the Nail Psoriasis Severity Index (NAPSI)

    NAPSI is a numeric, reproducible, objective tool for evaluation of nail psoriasis. This scale was used to evaluate the severity of nail bed psoriasis \& nail matrix psoriasis by area of involvement in the nail unit. Both fingernail \& toenail involvement were assessed.The nail is divided with imaginary horizontal \& longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0 to 4) \& nail matrix psoriasis (0 to 4), depending on the presence (score of 1) or absence (score of 0) of any of the features of nail bed \& nail matrix psoriasis in each quadrant: 0 = None 1. = present in one quadrant of nail 2. = present in two quadrants of nail 3. = present in three quadrants of nail 4. = present in four quadrants of nail NAPSI score of a nail is the sum of scores in nail bed \& nail matrix from each quadrant (maximum of 8). Each nail is evaluated, \& the sum of all the fingernails and toenails is the total NAPSI score ranging from 0 to 160 (No to Severe nail Psoriasis)

    Time frame: Baseline, Week 12

  9. Change From Baseline on the Psoriasis Scalp Severity Index (PSSI)

    The scalp was assessed for erythema (redness), induration (hardness), and desquamation (shedding of skin) and percentage of area affected as follows: Erythema, Induration and Desquamation: 0 = Absent 1. = Slight 2. = Moderate 3. = Severe 4. = Severest Possible Percent of Scalp Involved: 1. = \<10% 2. = 10% - 29% 3. = 30% - 49% 4. = 50% - 69% 5. = 70% - 89% 6. = 90% - 100% The PSSI score is a composite score derived from the sum of the scores for erythema, induration and desquamation multiplied by the score for the extent of scalp area involved (percent of scalp involved). The range is 0 (no psoriasis) to 72 (Most severe Disease). LSMean was calculated using treatment, region, baseline sPGA score, baseline weight category, baseline value, visit, treatment-by-visit, and baseline-by-visit interactions as fixed factors.

    Time frame: Baseline, Week 12

  10. Change From Baseline on the Palmoplantar Psoriasis Severity Index (PPASI)

    PPASI was used if the participant has palmoplantar psoriasis at baseline. Both the palms \& soles on each hand \& foot was assessed for erythema, induration, desquamation \& percentage of area affected as follows: Erythema (E), Induration (I), \& Desquamation (D):0 = None, 1 = Slight, 2 = Moderate, 3 = Severe, 4 = Very Severe Percent of Palm and Sole Area Covered: 0 = None, 1 = \<10%, 2 = 10% - 29%, 3 = 30% - 49%, 4 = 50% - 69%, 5 = 70% - 89%, 6 = 90% - 100% PPASI score is a composite score derived from the sum scores for E, I, \& D multiplied by a score for the extent of palm \& sole area involvement. The range is 0 (no psoriasis) to 72 (most severe disease).

    Time frame: Baseline, Week 12

  11. Number of Participants With Anti-Ixekizumab Antibodies

    A treatment emergent - antidrug antibody (TE-ADA) positive participant were defined as: 1. a participant with a \>= 4-fold increase over a positive baseline antibody titer; or 2. for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10.

    Time frame: Baseline through Week 48

  12. Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)

    Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss).

    Time frame: Week 12

  13. Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Etanercept Approved Countries)

    PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

    Time frame: Week 12

  14. Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Etanercept Approved Countries)

    Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.

    Time frame: Week 12

07

Results

Posted Mar 17, 2020

Participant flow

Double-Blind Treatment Period (Week 0 to Week 12), Open-Label Maintenance Period (Week 12 to Week 60), Extension Period (Week 60 to Week 108) followed by post-treatment follow-up period occurring from last treatment visit (week 108), or Early Termination Visit (ETV) for up to 24 weeks following that visit. Etanercept (ETN) is reference control group occurred only in Etanercept approved countries.

Double Blind Treatment Period
Participant flow — Double Blind Treatment Period
MilestonePBO (Double-Blinded Treatment Period)IXEQ4W (Double-Blinded Treatment Period)ETN (Double-Blinded Treatment Period)PBO/IXEQ4W (Maintenance Period)IXEQ4W/IXEQ4W (Maintenance Period)ETN/IXEQ4W (Maintenance Period)PBO/IXEQ4W/IXEQ4W (Extension Period)IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)ETN/IXEQ4W/IXEQ4W (Extension Period)PBO (Randomized Withdrawal Period)IXEQ4W (Randomized Withdrawal Period)IXEQ4W_Re-Treatment (Randomized Withdrawal) PeriodPBO (Post-Treatment Follow-Up)IXEQ4W (Post-Treatment Follow-Up)ETN (Post-Treatment Follow-Up)
Started5611530000000000000
Participants in etanercept approved countries193830000000000000
Completed5411430000000000000
Not completed210000000000000
Withdrew: Protocol violation100000000000000
Withdrew: Withdrawal by parent/guardian010000000000000
Withdrew: Withdrawal by subject100000000000000
Open-Label Maintenance Period
Participant flow — Open-Label Maintenance Period
MilestonePBO (Double-Blinded Treatment Period)IXEQ4W (Double-Blinded Treatment Period)ETN (Double-Blinded Treatment Period)PBO/IXEQ4W (Maintenance Period)IXEQ4W/IXEQ4W (Maintenance Period)ETN/IXEQ4W (Maintenance Period)PBO/IXEQ4W/IXEQ4W (Extension Period)IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)ETN/IXEQ4W/IXEQ4W (Extension Period)PBO (Randomized Withdrawal Period)IXEQ4W (Randomized Withdrawal Period)IXEQ4W_Re-Treatment (Randomized Withdrawal) PeriodPBO (Post-Treatment Follow-Up)IXEQ4W (Post-Treatment Follow-Up)ETN (Post-Treatment Follow-Up)
Started0005311328000000000
Completed0004910928000000000
Not completed000440000000000
Withdrew: Lost to follow-up000120000000000
Withdrew: Participant moved to another city000100000000000
Withdrew: Lack of efficacy000010000000000
Withdrew: Withdrawal by subject000210000000000
Extension Period
Participant flow — Extension Period
MilestonePBO (Double-Blinded Treatment Period)IXEQ4W (Double-Blinded Treatment Period)ETN (Double-Blinded Treatment Period)PBO/IXEQ4W (Maintenance Period)IXEQ4W/IXEQ4W (Maintenance Period)ETN/IXEQ4W (Maintenance Period)PBO/IXEQ4W/IXEQ4W (Extension Period)IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)ETN/IXEQ4W/IXEQ4W (Extension Period)PBO (Randomized Withdrawal Period)IXEQ4W (Randomized Withdrawal Period)IXEQ4W_Re-Treatment (Randomized Withdrawal) PeriodPBO (Post-Treatment Follow-Up)IXEQ4W (Post-Treatment Follow-Up)ETN (Post-Treatment Follow-Up)
Started00000034689000000
Completed00000031627000000
Not completed000000362000000
Withdrew: Lost to follow-up000000110000000
Withdrew: Sponsor decision000000001000000
Withdrew: Withdrawal by parent/guardian000000131000000
Withdrew: Withdrawal by subject000000120000000
Randomized Withdrawal Period
Participant flow — Randomized Withdrawal Period
MilestonePBO (Double-Blinded Treatment Period)IXEQ4W (Double-Blinded Treatment Period)ETN (Double-Blinded Treatment Period)PBO/IXEQ4W (Maintenance Period)IXEQ4W/IXEQ4W (Maintenance Period)ETN/IXEQ4W (Maintenance Period)PBO/IXEQ4W/IXEQ4W (Extension Period)IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)ETN/IXEQ4W/IXEQ4W (Extension Period)PBO (Randomized Withdrawal Period)IXEQ4W (Randomized Withdrawal Period)IXEQ4W_Re-Treatment (Randomized Withdrawal) PeriodPBO (Post-Treatment Follow-Up)IXEQ4W (Post-Treatment Follow-Up)ETN (Post-Treatment Follow-Up)
Started000000000333433000
Completed000000000333230000
Not completed000000000023000
Withdrew: Lost to follow-up000000000001000
Withdrew: Withdrawal by parent/guardian000000000001000
Withdrew: Withdrawal by subject000000000011000
Withdrew: Adverse event000000000010000
Post-Treatment Follow-Up Period
Participant flow — Post-Treatment Follow-Up Period
MilestonePBO (Double-Blinded Treatment Period)IXEQ4W (Double-Blinded Treatment Period)ETN (Double-Blinded Treatment Period)PBO/IXEQ4W (Maintenance Period)IXEQ4W/IXEQ4W (Maintenance Period)ETN/IXEQ4W (Maintenance Period)PBO/IXEQ4W/IXEQ4W (Extension Period)IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)ETN/IXEQ4W/IXEQ4W (Extension Period)PBO (Randomized Withdrawal Period)IXEQ4W (Randomized Withdrawal Period)IXEQ4W_Re-Treatment (Randomized Withdrawal) PeriodPBO (Post-Treatment Follow-Up)IXEQ4W (Post-Treatment Follow-Up)ETN (Post-Treatment Follow-Up)
Started00000000000061662
Completed00000000000061391
Not completed0000000000000271
Withdrew: Adverse event000000000000020
Withdrew: Lost to follow-up000000000000010
Withdrew: Participant moved to another city000000000000010
Withdrew: Protocol violation000000000000010
Withdrew: Site terminated by sponsor000000000000001
Withdrew: Withdrawal by parent/guardian0000000000000110
Withdrew: Withdrawal by subject000000000000090
Withdrew: Other-determined by investigator000000000000020

Outcome measures

PrimaryPercentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)

PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total body surface area (BSA) affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)
percentage of participantsPlaceboIxekizumab
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)2588.7
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 63.7 · 95% CI 51.0 to 76.4
PrimaryPercentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab)

Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab)
percentage of participantsPlaceboIxekizumab
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab)10.780.9
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 70.2 · 95% CI 59.3 to 81
SecondaryPercentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)

PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%.Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
percentage of participantsPlaceboIxekizumab
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)5.478.3
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 72.9 · 95% CI 63.3 to 82.5
SecondaryPercentage of Participants With a sPGA (0)

Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis. An sPGA assessed as 0 represents a clinically important endpoint indicating complete resolution of plaque psoriasis.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a sPGA (0)
percentage of participantsPlaceboIxekizumab
Percentage of Participants With a sPGA (0)1.852.2
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 50.4 · 95% CI 40.6 to 60.2
SecondaryPercentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
percentage of participantsPlaceboIxekizumab
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)1.849.6
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 47.8 · 95% CI 38.0 to 57.6
SecondaryPercentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)

PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
percentage of participantsPlaceboIxekizumab
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)8.953.9
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 45 · 95% CI 33.2 to 56.8
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) (0,1)

Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1)
percentage of participantsPlaceboIxekizumab
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1)7.147.8
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 40.7 · 95% CI 29.3 to 52.0
SecondaryPercentage of Participants With an Improvement of ≥4 in Those Who Had a Baseline Itch Numeric Rating Scale (NRS) Score of ≥4

Itch Numeric Rating Scale (NRS): is a single-item, patient-reported outcome (PRO) measure designed to capture the overall severity of a participant's itching due to his/her psoriasis by having the patient circle the integer that describes the worst level of itching in the past 24 hours on an 11-point NRS anchored at 0 representing "no itching" and 10 representing "worst itch imaginable.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an Improvement of ≥4 in Those Who Had a Baseline Itch Numeric Rating Scale (NRS) Score of ≥4
percentage of participantsPlaceboIxekizumab
Percentage of Participants With an Improvement of ≥4 in Those Who Had a Baseline Itch Numeric Rating Scale (NRS) Score of ≥420.071.1
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 51.1 · 95% CI 35.3 to 66.9
SecondaryPercentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) (0/1)

DLQI is a validated, dermatology-specific, patient reported measure that evaluates participant's health-related quality of life. It consists of 10 items that are grouped in 6 domains: symptoms \& feelings, daily activities, leisure, work \& school , personal relationships, \& treatment. The recall period of this scale is over the "last week." Response categories and corresponding scores are: Very much = 3, A lot = 2, A little = 1, Not at all = 0, Not relevant = 0. A DLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment). CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. A CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) (0/1)
percentage of participantsPlaceboIxekizumab
Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) (0/1)23.264.3
Statistical analysis
  • Placebo vs Ixekizumab · Fisher Exact · p = <0.001 · Mean difference (final values): 41.1 · 95% CI 27.0 to 55.2
SecondaryChange From Baseline on the Nail Psoriasis Severity Index (NAPSI)

NAPSI is a numeric, reproducible, objective tool for evaluation of nail psoriasis. This scale was used to evaluate the severity of nail bed psoriasis \& nail matrix psoriasis by area of involvement in the nail unit. Both fingernail \& toenail involvement were assessed.The nail is divided with imaginary horizontal \& longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0 to 4) \& nail matrix psoriasis (0 to 4), depending on the presence (score of 1) or absence (score of 0) of any of the features of nail bed \& nail matrix psoriasis in each quadrant: 0 = None 1. = present in one quadrant of nail 2. = present in two quadrants of nail 3. = present in three quadrants of nail 4. = present in four quadrants of nail NAPSI score of a nail is the sum of scores in nail bed \& nail matrix from each quadrant (maximum of 8). Each nail is evaluated, \& the sum of all the fingernails and toenails is the total NAPSI score ranging from 0 to 160 (No to Severe nail Psoriasis)

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Nail Psoriasis Severity Index (NAPSI)
score on a scalePlaceboIxekizumab
Change From Baseline on the Nail Psoriasis Severity Index (NAPSI)0.17 ± 5.331-16.87 ± 3.110
Statistical analysis
  • Placebo vs Ixekizumab · Mixed Models Analysis · p = 0.005 · Mean difference (final values): -17.04 · 95% CI -28.70 to -5.38
SecondaryChange From Baseline on the Psoriasis Scalp Severity Index (PSSI)

The scalp was assessed for erythema (redness), induration (hardness), and desquamation (shedding of skin) and percentage of area affected as follows: Erythema, Induration and Desquamation: 0 = Absent 1. = Slight 2. = Moderate 3. = Severe 4. = Severest Possible Percent of Scalp Involved: 1. = \<10% 2. = 10% - 29% 3. = 30% - 49% 4. = 50% - 69% 5. = 70% - 89% 6. = 90% - 100% The PSSI score is a composite score derived from the sum of the scores for erythema, induration and desquamation multiplied by the score for the extent of scalp area involved (percent of scalp involved). The range is 0 (no psoriasis) to 72 (Most severe Disease). LSMean was calculated using treatment, region, baseline sPGA score, baseline weight category, baseline value, visit, treatment-by-visit, and baseline-by-visit interactions as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Psoriasis Scalp Severity Index (PSSI)
score on a scalePlaceboIxekizumab
Change From Baseline on the Psoriasis Scalp Severity Index (PSSI)-12.28 ± 2.572-27.64 ± 2.320
Statistical analysis
  • Placebo vs Ixekizumab · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -15.36 · 95% CI -18.69 to -12.04
SecondaryChange From Baseline on the Palmoplantar Psoriasis Severity Index (PPASI)

PPASI was used if the participant has palmoplantar psoriasis at baseline. Both the palms \& soles on each hand \& foot was assessed for erythema, induration, desquamation \& percentage of area affected as follows: Erythema (E), Induration (I), \& Desquamation (D):0 = None, 1 = Slight, 2 = Moderate, 3 = Severe, 4 = Very Severe Percent of Palm and Sole Area Covered: 0 = None, 1 = \<10%, 2 = 10% - 29%, 3 = 30% - 49%, 4 = 50% - 69%, 5 = 70% - 89%, 6 = 90% - 100% PPASI score is a composite score derived from the sum scores for E, I, \& D multiplied by a score for the extent of palm \& sole area involvement. The range is 0 (no psoriasis) to 72 (most severe disease).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Palmoplantar Psoriasis Severity Index (PPASI)
score on a scalePlaceboIxekizumab
Change From Baseline on the Palmoplantar Psoriasis Severity Index (PPASI)6.89 ± 3.37-5.11 ± 2.148
Statistical analysis
  • Placebo vs Ixekizumab · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -12.01 · 95% CI -20.11 to -3.90
SecondaryNumber of Participants With Anti-Ixekizumab Antibodies

A treatment emergent - antidrug antibody (TE-ADA) positive participant were defined as: 1. a participant with a \>= 4-fold increase over a positive baseline antibody titer; or 2. for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10.

Time frame:
Baseline through Week 48
Reported as:
Number · participants
Number of Participants With Anti-Ixekizumab Antibodies
participantsIxekizumab (Maintenance Period)
Number of Participants With Anti-Ixekizumab Antibodies56
SecondaryPharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)

Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss).

Time frame:
Week 12
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)
microgram per milliliter (μg/mL)Ixekizumab
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)3.03 ± 106
SecondaryPercentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Etanercept Approved Countries)

PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Etanercept Approved Countries)
percentage of participantsPlaceboIxekizumabOpen-Label Etanercept
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Etanercept Approved Countries)26.384.263.3
Statistical analysis
  • Ixekizumab vs Open-Label Etanercept · Fisher Exact · p = 0.089 · Mean difference (final values): 20.9 · 95% CI 0.1 to 41.7
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Etanercept Approved Countries)

Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Etanercept Approved Countries)
percentage of participantsPlaceboIxekizumabOpen-Label Etanercept
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Etanercept Approved Countries)5.376.353.3
Statistical analysis
  • Ixekizumab vs Open-Label Etanercept · Fisher Exact · p = 0.070 · Mean difference (final values): 23.0 · 95% CI 0.6 to 45.4

Adverse events

Collected over Up to 132 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PBO (Double-Blinded Treatment Period)0/56 (0%)0/56 (0%)14/56 (25%)
IXEQ4W (Double-Blinded Treatment Period)0/115 (0%)1/115 (0.9%)49/115 (42.6%)
ETN (Double-Blinded Treatment Period)0/30 (0%)1/30 (3.3%)7/30 (23.3%)
PBO/IXEQ4W (Maintenance Period)0/53 (0%)3/53 (5.7%)33/53 (62.3%)
IXEQ4W/IXEQ4W (Maintenance Period)0/113 (0%)7/113 (6.2%)76/113 (67.3%)
ETN/IXEQ4W (Maintenance Period)0/28 (0%)1/28 (3.6%)18/28 (64.3%)
PBO/IXEQ4W/IXEQ4W (Extension Period)0/34 (0%)0/34 (0%)20/34 (58.8%)
IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)0/68 (0%)2/68 (2.9%)43/68 (63.2%)
ETN/IXEQ4W/IXEQ4W (Extension Period)0/9 (0%)0/9 (0%)5/9 (55.6%)
PBO (Randomized Withdrawal Period)0/33 (0%)0/33 (0%)15/33 (45.5%)
IXEQ4W (Randomized Withdrawal Period)0/34 (0%)3/34 (8.8%)22/34 (64.7%)
IXEQ4W_Re-Treatment (Randomized Withdrawal) Period0/33 (0%)0/33 (0%)11/33 (33.3%)
PBO (Post-Treatment Follow-Up)0/6 (0%)0/6 (0%)2/6 (33.3%)
IXEQ4W (Post-Treatment Follow-Up)0/166 (0%)1/166 (0.6%)9/166 (5.4%)
ETN (Post-Treatment Follow-Up)0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPBO (Double-Blinded Treatment Period)IXEQ4W (Double-Blinded Treatment Period)ETN (Double-Blinded Treatment Period)PBO/IXEQ4W (Maintenance Period)IXEQ4W/IXEQ4W (Maintenance Period)ETN/IXEQ4W (Maintenance Period)PBO/IXEQ4W/IXEQ4W (Extension Period)IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)ETN/IXEQ4W/IXEQ4W (Extension Period)PBO (Randomized Withdrawal Period)IXEQ4W (Randomized Withdrawal Period)IXEQ4W_Re-Treatment (Randomized Withdrawal) PeriodPBO (Post-Treatment Follow-Up)IXEQ4W (Post-Treatment Follow-Up)ETN (Post-Treatment Follow-Up)
Herpes zoster oticusInfections and infestations0/560/1150/300/530/1131/280/340/680/90/330/340/330/60/1660/2
OverdoseInjury, poisoning and procedural complications0/560/1151/300/530/1130/280/340/680/90/330/340/330/60/1660/2
FuruncleInfections and infestations0/560/1150/300/530/1130/280/340/680/90/331/340/330/60/1660/2
AstrocytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/560/1150/300/530/1130/280/340/680/90/331/340/330/60/1660/2
EpilepsyNervous system disorders0/560/1150/300/530/1130/280/340/680/90/331/340/330/60/1660/2
PregnancyPregnancy, puerperium and perinatal conditions0/360/630/181/350/610/170/220/370/30/170/230/190/20/1040/1
Inflammatory bowel diseaseGastrointestinal disorders0/560/1150/301/530/1130/280/340/680/90/330/340/330/60/1660/2
TonsillitisInfections and infestations0/560/1150/301/530/1130/280/340/680/90/330/340/330/60/1660/2
Crohn's diseaseGastrointestinal disorders0/560/1150/300/532/1130/280/340/680/90/330/340/330/61/1660/2
DehydrationMetabolism and nutrition disorders0/560/1150/300/532/1130/280/340/680/90/330/340/330/60/1660/2
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPBO (Double-Blinded Treatment Period)IXEQ4W (Double-Blinded Treatment Period)ETN (Double-Blinded Treatment Period)PBO/IXEQ4W (Maintenance Period)IXEQ4W/IXEQ4W (Maintenance Period)ETN/IXEQ4W (Maintenance Period)PBO/IXEQ4W/IXEQ4W (Extension Period)IXEQ4W/IXEQ4W/IXEQ4W (Extension Period)ETN/IXEQ4W/IXEQ4W (Extension Period)PBO (Randomized Withdrawal Period)IXEQ4W (Randomized Withdrawal Period)IXEQ4W_Re-Treatment (Randomized Withdrawal) PeriodPBO (Post-Treatment Follow-Up)IXEQ4W (Post-Treatment Follow-Up)ETN (Post-Treatment Follow-Up)
NasopharyngitisInfections and infestations4/5613/1150/307/5316/1134/280/348/680/94/3311/342/330/61/1660/2
Upper respiratory tract infectionInfections and infestations4/566/1150/305/5313/1132/2810/3411/680/93/331/342/330/60/1660/2
Injection site reactionGeneral disorders0/5611/1150/308/5320/1130/280/342/680/90/330/341/330/60/1660/2
BronchitisInfections and infestations0/560/1151/301/530/1131/283/341/680/90/330/340/331/60/1660/2
CellulitisInfections and infestations1/560/1150/300/530/1130/280/340/680/90/330/340/331/60/1660/2
Gastroenteritis viralInfections and infestations0/560/1150/300/534/1132/280/340/680/90/330/340/331/60/1660/2
PharyngitisInfections and infestations0/562/1152/302/538/1134/283/342/681/92/331/342/330/60/1660/2
TonsillitisInfections and infestations2/561/1150/301/535/1134/281/344/680/91/333/342/330/60/1660/2
Irritable bowel syndromeGastrointestinal disorders0/560/1150/300/530/1130/280/340/681/90/330/341/330/60/1660/2
InfluenzaInfections and infestations0/562/1152/301/534/1130/281/344/681/90/331/340/330/61/1660/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboIxekizumabOpen-label EtanerceptTotal
Mean13.1 ± 2.7913.7 ± 3.1413.7 ± 2.9513.5 ± 3.02
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIxekizumabOpen-label EtanerceptTotal
Female366318117
Male20521284
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIxekizumabOpen-label EtanerceptTotal
Hispanic or Latino1130748
Not Hispanic or Latino428223147
Unknown or Not Reported3306
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIxekizumabOpen-label EtanerceptTotal
American Indian or Alaska Native0213
Asian2406
Native Hawaiian or Other Pacific Islander0000
Black or African American3306
White459525165
More than one race310316
Unknown or Not Reported3115
Region of Enrollment
Region of Enrollment(Participants)PlaceboIxekizumabOpen-label EtanerceptTotal
Puerto Rico3508
Argentina37313
Hungary613221
United States2242064
Czechia26412
Spain54312
Russia47415
Canada1607
Netherlands0101
Poland512825
Mexico1427
France1113
Germany37313
Psoriasis Area Severity Index (PASI)
Psoriasis Area Severity Index (PASI)(Score on a scale)PlaceboIxekizumabOpen-label EtanerceptTotal
Mean19.73 ± 8.01019.75 ± 7.50924.78 ± 7.44820.49 ± 7.81
(sPGA)
(sPGA)(Score on a scale)PlaceboIxekizumabOpen-label EtanerceptTotal
Mean3.5 ± 0.633.6 ± 0.614.1 ± 0.313.63 ± 0.61
08

Study locations

69 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Tien Q. Nguyen, MD inc. DBA First OC Dermatology
    Fountain Valley, California 92708, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32256, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Forward Clinical Trials, Inc
    Tampa, Florida 33624, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • SSM Health Cardinal Glennon Children's Hospital
    Saint Louis, Missouri 63104, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • University of North Carolina Dermatology and skin Cancer Cen
    Chapel Hill, North Carolina 27516, United States
  • Wright State Physicians Dermatology
    Fairborn, Ohio 45324, United States
  • Ohio State Univ College Of Medicine
    Gahanna, Ohio 43230, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Dermatology and Skin Surgery Center
    Exton, Pennsylvania 19341, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23502, United States
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1056ABJ, Argentina
  • Fundación Estudios Clínicos- Servicio de Dermatología
    Rosario, Santa Fe 5200, Argentina
  • Instituto de Neumonología y Dermatología
    Buenos Aires, C1425BEA, Argentina
  • Psoriahue Medicina Interdisciplinaria
    Buenos Aires, C1425DKG, Argentina
  • Institute for Skin Advancement
    Calgary, Alberta T3A 2N1, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P1X2, Canada
  • K. Papp Clinical Research Inc
    Waterloo, Ontario N2J 1C4, Canada
  • Hospital Ste Justine
    Montreal, Quebec H3T 1C5, Canada
  • Detska fakultni nemocnice
    Brno, 613 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni Nemocnice Plzen
    Plzen-Bory, 305 99, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Nemocnice Na Bulovce
    Praha 8, 180 81, Czechia
  • LF UK - Fakultni poliklinika
    Praha, 120 00, Czechia
  • Centre hospitalier universitaire Pellegrin
    Bordeaux, 33076, France
  • Hôpital Femme Mère Enfant
    Bron, 69500, France
  • CHU de Nice Hopital de L'Archet
    Nice, 06202, France
  • Universitätsklinikum Erlangen
    Erlangen, Bayern 91054, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Universitätsklinikum Münster
    Münster, Nordrhein-Westfalen 48149, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
  • ISA GmbH
    Berlin, 10789, Germany
  • SZTE AOK Borgyogyaszati es Allergologiai Klinika
    Szeged, Csongrad 6720, Hungary
  • Debreceni Egyetem Klinikai Kozpont Borgyogyaszati Klinika
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Allergo-Derm Bakos Kft
    Szolnok, Jasz-Nagykun-Szolnok 5000, Hungary
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
    Budapest, 1123, Hungary
  • Oroshaza Varosi Onkormanyzat Korhaza
    Oroshaza, 5901, Hungary
  • Hospital Infantil de Mexico
    Ciudad de Mexico, Federal District 06720, Mexico
  • Hospital Univ. Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo León 64460, Mexico
  • RM Pharma Specialists S.A. de C.V.
    Distrito Federal, 3100, Mexico
  • Arke Estudios Clinicos S.A. de C.V.
    Veracruz, 91910, Mexico
  • Universitair Medisch Centrum St Radboud Nijmegen
    Nijmegen, 6525 GL, Netherlands
  • "Dermed" Centrum Medyczne Sp. z o.o.
    Lodz, 90-265, Poland
  • Centralny Szpital Kliniczny MSW
    Warszawa, 02-507, Poland
  • DermMEDICA Sp. z o.o.
    Wroclaw, 51-318, Poland
  • Office of Dr. Samuel Sanchez PSC
    Caguas, 00727, Puerto Rico
  • Grupo Dermatologico de Carolina
    Carolina, 00985, Puerto Rico
  • Ponce School of Medicine CAIMED Center
    Ponce, 00716, Puerto Rico
  • GCM Medical Group PSC
    San Juan, 00917, Puerto Rico
  • GBUZ Clinical dermatology and venereological dispensary
    Krasnodar, 350000, Russian Federation
  • Center of Children's Health
    Moscow, 119991, Russian Federation
  • Hospital Sant Joan de Déu
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
09

References and documents

Publications

  • Paller AS, Seyger MMB, Magarinos GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS Investigators. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. JAMA Dermatol. 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655. Erratum In: JAMA Dermatol. 2022 Oct 1;158(10):1221. doi: 10.1001/jamadermatol.2022.3698. PubMed 35416908 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Feb 2019, 22 months.

Results were first posted in Mar 2020, 1 year 1 month after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2017
First posted
Mar 8, 2017
StartActual
Mar 28, 2017
Primary completionActual
Feb 7, 2019
CompletionActual
Mar 23, 2021
Results first posted
Mar 17, 2020
Last update
Sep 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03073200
Responsible party
Sponsor
First posted
Mar 8, 2017
Start date
Mar 28, 2017
Primary completion
Feb 7, 2019
Completion
Mar 23, 2021
Results posted
Mar 17, 2020
Last update
Sep 27, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixekizumab · Etanercept

Start the discussion